MetLife Investment Management’s Fulgent Genetics FLGT Stock Holding History

MetLife Investment Management’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$200K	Hold	12,579	–	–	﹤0.01%	2228
2025 Q4	$330K	Hold	12,579	–	–	﹤0.01%	2005
2025 Q3	$284K	Hold	12,579	–	–	﹤0.01%	2118
2025 Q2	$250K	Sell	12,579 -276	-2%	-$5.38K	﹤0.01%	2068
2025 Q1	$217K	Hold	12,855	–	–	﹤0.01%	2155
2024 Q4	$237K	Hold	12,855	–	–	﹤0.01%	2213
2024 Q3	$279K	Hold	12,855	–	–	﹤0.01%	2108
2024 Q2	$252K	Buy	12,855 +1,099	+9%	+$22.9K	﹤0.01%	2103
2024 Q1	$255K	Hold	11,756	–	–	﹤0.01%	2059
2023 Q4	$340K	Hold	11,756	–	–	﹤0.01%	1917
2023 Q3	$314K	Hold	11,756	–	–	﹤0.01%	1917
2023 Q2	$435K	Hold	11,756	–	–	﹤0.01%	1788
2023 Q1	$367K	Hold	11,756	–	–	﹤0.01%	1845
2022 Q4	$350K	Hold	11,756	–	–	﹤0.01%	1870
2022 Q3	$448K	Hold	11,756	–	–	﹤0.01%	1721
2022 Q2	$641K	Hold	11,756	–	–	0.01%	1491
2022 Q1	$734K	Buy	11,756 +4,339	+59%	+$286K	﹤0.01%	1530
2021 Q4	$746K	Hold	7,417	–	–	0.01%	1273
2021 Q3	$667K	Hold	7,417	–	–	0.01%	1362
2021 Q2	$684K	Buy	7,417 +2,364	+47%	+$189K	0.01%	1392
2021 Q1	$488K	Hold	5,053	–	–	﹤0.01%	1536
2020 Q4	$263K	Hold	5,053	–	–	﹤0.01%	1832
2020 Q3	$202K	Buy	+5,053	New	+$158K	﹤0.01%	1859

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MetLife Investment Management's FLGT Position: Q1 2026 in Review

MetLife Investment Management held its Fulgent Genetics (FLGT) position steady in Q1 2026 at 12,579 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #2228.

MetLife Investment Management first reported a position in FLGT in Q3 2020 and has held it in 23 quarters since. The position peaked at $746K in Q4 2021. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

MetLife Investment Management held 12,579 shares of Fulgent Genetics worth $200K as of Q1 2026.
MetLife Investment Management left its Fulgent Genetics share count unchanged in Q1 2026.
Fulgent Genetics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2228 holding.
MetLife Investment Management first reported a position in Fulgent Genetics in Q3 2020 and has held it in 23 quarters since.
MetLife Investment Management's Fulgent Genetics position peaked at $746K in Q4 2021.
157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.